1. Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
- Author
-
de Marinis F, Vergnenegre A, Passaro A, Dubos-Arvis C, Carcereny E, Drozdowskyj A, Zeaiter A, Perez-Moreno P, and Rosell R
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung mortality, Erlotinib Hydrochloride, Exanthema drug therapy, Exanthema epidemiology, Exanthema prevention & control, Humans, Incidence, Kaplan-Meier Estimate, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Quinazolines administration & dosage, Time Factors, Treatment Outcome, Carcinoma, Non-Small-Cell Lung complications, Carcinoma, Non-Small-Cell Lung genetics, ErbB Receptors genetics, Exanthema etiology, Lung Neoplasms complications, Lung Neoplasms genetics, Mutation, Quinazolines adverse effects
- Abstract
Aim: This analysis investigates incidence and time course of rash in the EURTAC study., Materials & Methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy., Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment., Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.
- Published
- 2015
- Full Text
- View/download PDF